/-/media/corpsite/assets/park-life/news-and-events/news/logo/hkstp_logo_en_op-dark-mode.svg?mw=1980&rev=578e4e3c3c8a43ae96060191588e8ecc&hash=CDDFB54416A7577AAA399A746252CD83
GenEditBio Limited9f39f8fc-fb09-ec11-8142-0050569a2b20_CompanyLogo_30072026
Biomedical Technology

GenEditBio Limited

Company

GenEditBio is a clinical-stage gene therapy startup with a strategic goal of developing in vivo genome-editing therapeutic solutions (dubbed “DNA surgery”) that are fundamentally safe, precise, efficacious, and affordable for genetic diseases with unmet needs. The Company is established in 2021 and headquartered in Hong Kong, China.

Product

GenEditBio’s lead clinical asset, GEB-101, is an investigational first-in-class somatic genome-editing drug candidate designed as a one-and-done treatment for TGFBI-related corneal dystrophies. GEB-101 has received regulatory investigational new drug (IND) clearances from China and the U.S.

Technology

GenEditBio focuses on three core R&D areas: (1) novel Cas nucleases; (2) safe and efficient in vivo cargo delivery utilising engineered protein delivery vehicle (PDV) and lipid nanoparticle (LNP); and (3) unbiased off-target and PAM analysis methods (GUIDE-Seq, EDITED-Seq, and GenomePAM)

Explore other companies

directory-icon
Biomedical Technology
Homing Therapeutics Limited
directory-icon
Biomedical Technology
Apeiron Therapeutics (Hong Kong) Limited
directory-icon
Biomedical Technology
Base Therapeutics (HK), Limited
Beth Bioinformatics Co LimitedProfilePic55271
Biomedical Technology
Beth Bioinformatics Co., Limited
Hong Kong Science & Technology Parks Corporation - Company Directory - GenEditBio Limited
Company Directory
INNOVIS

Hi! I’m INNOVIS, and I'm here to help. Please let me know what you're looking for.